90 related articles for article (PubMed ID: 26094944)
1. Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
Mizuguchi T; Ohashi N; Nomura W; Komoriya M; Hashimoto C; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2015 Aug; 23(15):4423-4427. PubMed ID: 26094944
[TBL] [Abstract][Full Text] [Related]
2. Development of anti-HIV peptides based on a viral capsid protein.
Mizuguchi T; Ohashi N; Matsumoto D; Hashimoto C; Nomura W; Yamamoto N; Murakami T; Tamamura H
Biopolymers; 2017 Jan; 108(1):. PubMed ID: 27428649
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.
Narumi T; Komoriya M; Hashimoto C; Wu H; Nomura W; Suzuki S; Tanaka T; Chiba J; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2012 Feb; 20(4):1468-74. PubMed ID: 22277590
[TBL] [Abstract][Full Text] [Related]
4. Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.
Tsuji K; Owusu KB; Kobayakawa T; Wang R; Fujino M; Kaneko M; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2020 Jun; 28(11):115488. PubMed ID: 32305183
[TBL] [Abstract][Full Text] [Related]
5. Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.
Tsuji K; Wang R; Kobayakawa T; Owusu KB; Fujino M; Kaneko M; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2021 Jan; 30():115923. PubMed ID: 33316719
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity.
Savarino A; Gennero L; Chen HC; Serrano D; Malavasi F; Boelaert JR; Sperber K
AIDS; 2001 Nov; 15(17):2221-9. PubMed ID: 11698694
[TBL] [Abstract][Full Text] [Related]
7. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
8. Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller.
Chevigne A; Delhalle S; Counson M; Beaupain N; Rybicki A; Verschueren C; Staub T; Schmit JC; Seguin-Devaux C; Deroo S
AIDS; 2016 Jan; 30(3):377-82. PubMed ID: 26760231
[TBL] [Abstract][Full Text] [Related]
9. Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.
Jia Q; Jiang X; Yu F; Qiu J; Kang X; Cai L; Li L; Shi W; Liu S; Jiang S; Liu K
Bioorg Med Chem Lett; 2012 Apr; 22(7):2393-5. PubMed ID: 22406118
[TBL] [Abstract][Full Text] [Related]
10. Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.
Danial M; van Dulmen TH; Aleksandrowicz J; Pötgens AJ; Klok HA
Bioconjug Chem; 2012 Aug; 23(8):1648-60. PubMed ID: 22770564
[TBL] [Abstract][Full Text] [Related]
11. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
Shi W; Cai L; Lu L; Wang C; Wang K; Xu L; Zhang S; Han H; Jiang X; Zheng B; Jiang S; Liu K
Chem Commun (Camb); 2012 Dec; 48(94):11579-81. PubMed ID: 23093045
[TBL] [Abstract][Full Text] [Related]
12. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
[TBL] [Abstract][Full Text] [Related]
13. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
14. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
[TBL] [Abstract][Full Text] [Related]
15. α-Aminoisobutyric acid incorporation induces cell permeability and antiviral activity of HIV-1 major homology region fragments.
Lampel A; Elis E; Guterman T; Shapira S; Marco P; Bacharach E; Gazit E
Chem Commun (Camb); 2015 Aug; 51(62):12349-52. PubMed ID: 26121332
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, antiviral activity, and pre-formulation development of poly-L-arginine-fatty acyl derivatives of nucleoside reverse transcriptase inhibitors.
Pemmaraju BP; Malekar S; Agarwal HK; Tiwari RK; Oh D; Doncel GF; Worthen DR; Parang K
Nucleosides Nucleotides Nucleic Acids; 2015; 34(1):1-15. PubMed ID: 25513860
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide.
Lee MK; Kim HK; Lee TY; Hahm KS; Kim KL
Exp Mol Med; 2006 Feb; 38(1):18-26. PubMed ID: 16520549
[TBL] [Abstract][Full Text] [Related]
18. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
[TBL] [Abstract][Full Text] [Related]
19. Gold(I) complex of 1,1'-bis(diphenylphosphino) ferrocene-quinoline conjugate: a virostatic agent against HIV-1.
Gama N; Kumar K; Ekengard E; Haukka M; Darkwa J; Nordlander E; Meyer D
Biometals; 2016 Jun; 29(3):389-97. PubMed ID: 26922346
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
